Mace L. Rothenberg, MD Home - About Antigenics - Leadership > Mace L.
Aroplatin liposomal platinum agent Home - Products & Technologies - Cancer Products Aroplatin™ liposomal platinum agent An investigational product What is Aroplatin?Eloxatin ® (oxaliplatin, Sanofi-Aventis ), an approved treatment for colorectal cancer.
Antigenics Company Overview page 2
Antigenics Company Overview PHASE 3 DATA FOR ONCOPHAGE IN NONMETASTATIC RENAL CELL CARCINOMA SHOW 45- PERCENT IMPROVEMENT IN RECURRENCE- FREE SURVIVAL IN INTERMEDIATE- RISK PATIENTS IN PHASE 3 TRIAL OF ONCOPHAGE IN METASTATIC MELANOMA, OVERALL MEDIAN SURVIVAL WAS 29 PERCENT LONGER IN PATIENTS WHO RECEIVED AT LEAST 10 INJECTIONS OF ONCOPHAGE PHASE 2, INVESTIGATOR- SPONSORED TRIAL OF ONCOPHAGE IN GLIOMA ONGOING...
2006_AGEN_10K_full.pdf page 18
author: ayildiz
duplicates:http://www.antigenics.com/investors/sec/10k/2006_AGEN_10-K.pdf
Access Pharmaceuticals Corporate Presentation May 2006 page 20
author: David Nowotnik
Aroplatin_04-20-2006.qxd Product Profile: AROPLATINª MAY 2006 NEXT- GENERATION COMPOUND Platinum compounds have become mainstays of cancer chemotherapy and have proven effective against many types of solid tumor.oxaliplatin has been associated with dose- limiting neurotoxicity.
http://corpcomm.amgen.com/abgenix/releases/2005-04-26a.html Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy For First- Line Treatment of Metastatic Colorectal Cancer Study Evaluates Panitumumab Administered With Bevacizumab and Chemotherapy THOUSAND OAKS, Calif.
author: pmannle
http://corpcomm.amgen.com/abgenix/releases/2005-04-26a.html page 1
author: pmannle
GPC-Biotech Home Deutsch About the Company Anticancer Programs Technologies Investor Relations News &-Media Careers Calendar Contact/- Imprint Sitemap Search Glossary Forward Look-ing Statements Overview Strategy Executive Committee Supervisory Board Locations Overview Satraplatin Monoclonal Antibody Cdk Inhibitors Research Programs Growing the Pipeline Alliances Stock Key Figures Financial...
author: Form+Fakten, Maximilian Vollendorf
GPC-Biotech Home Deutsch About the Company Anticancer Programs Technologies Investor Relations News &-Media Careers Calendar Contact/- Imprint Sitemap Search Glossary Forward Look-ing Statements Overview Strategy Executive Committee Supervisory Board Locations Overview Satraplatin Monoclonal Antibody Cdk Inhibitors Research Programs Growing the Pipeline Alliances Stock Key Figures Financial...
author: Form+Fakten, Maximilian Vollendorf
GPC-Biotech Debiopharm developed, for example, the blockbuster anticancer drug Eloxatin ® (oxaliplatin) and has shown that it can bring drugs to the market successfully.- While GPC Biotech has focused its internal development efforts on oncology, the partnering of this program also shows the value of our earlier research in other indications such as autoimmune diseases.- There...
author: Form+Fakten, Maximilian Vollendorf
GPC-Biotech Home Deutsch About the Company Anticancer Programs Technologies Investor Relations News &-Media Careers Calendar Contact/- Imprint Sitemap Search Glossary Forward Look-ing Statements Overview Strategy Executive Committee Supervisory Board Locations Overview Satraplatin Monoclonal Antibody Cdk Inhibitors Research Programs Growing the Pipeline Alliances Stock Key Figures Financial...
author: Form+Fakten, Maximilian Vollendorf
Oxaliplatin - [Medication] - Quest Diagnostics Patient Health Library Oxaliplatin Examples Brand Name Chemical Name Eloxatin oxaliplatin How It Works Oxaliplatin interrupts cancer cell growth and slows the spread of cancer cells in the body.Oxaliplatin - [Medication] - Quest Diagnostics...
3rdWorld 6% for Not yet met; compiling cytarabine meningitis cytarabine unencapsulated and analyzing the liposomal Phase IV data Doxil Metastatic ovarian 6/ 28/ 99 Sequus (now J& J) Response rate (study 1): 22.2% Met doxorubicin carcinoma Response rate (study 2): 17.1% liposomal Response rate (study 3): 0% Doxil AIDS- related Kaposi's 11/ 17/ 95 Sequus (now J& J) PR (34 evaluable patients for...
author: tracy
subject: 3rdWorld
3rdWorld page 8
author: tracy
subject: 3rdWorld
BioPortfolio Limited Datamonitor Oncology Reports Scope The evolving use of docetaxel and paclitaxel for the treatment of breast cancer The role of adjuvant chemotherapy and innovative drugs in non-small cell lung cancer (NSCLC) The impact of new agents such as Roche’s Xeloda and Sanofi-Synthelabo’s Eloxatin on gold standard therapy for colorectal cancer Report Highlights The superiority of docetaxel over...
Oxford Biomedica Announces Encouraging Results From Three Phase Ii Trials Of Trovax In Patients With Colorectal Cancer - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
OXFORD BIOMEDICA ANNOUNCES POSITIVE INTERIM PHASE II RESULTS WITH TROVAX IN COLORECTAL CANCER - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
BioPortfolio Limited 99 Surprisingly low use of gemcitabine with oxaliplatin, considering benefits 99 Fluorouracil and gemcitabine do not display synergy 100 No clinical benefit from gemcitabine and cisplatin 101 Oxaliplatin is a close second in France 101 Unexplained high use of cisplatin in Italy 101 CHAPTER 9 CLINICAL TRIAL INVOLVEMENT 103 Neoadjuvant and/or adjuvant drug therapy 103 Low...
BioPortfolio Limited However, Lilly’s Alimta has the potential to replace 5-FU as the core drug for colorectal cancer treatment 11 Key metrics 13 Summary of research/clinical and commercial attractiveness of launched and Phase III drugs for colorectal cancer 15 CHAPTER 2 COLORECTAL CANCER OVERVIEW 22 The colon and rectum 22 Causes of colorectal cancer 23 Risk factors of colorectal cancer 23...
BioPortfolio Limited Pharmaceutical companies with pipeline products seeking to enter the colorectal cancer market should conduct clinical trials in combination with these cytotoxic agents to ensure a smooth entry into the market 7 Key metrics 10 Key market events during 2003/2004 11 Taxotere gains ground on Taxol 11 Taxol’s patent expiry in the EU 11 The rise of Eloxatin 11 Alimta and Gemzar...
BioPortfolio Limited Commercial Insight: Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market TABLE OF CONTENTS About Datamonitor Healthcare 2 CHAPTER 1 EXECUTIVE SUMMARY 3 CHAPTER 2 MARKET DEFINITION AND OVERVIEW 12 Scope 12 Market definition for this report 12 Cytotoxics 13 L1A – Alkylating agents 13 L1B – Antimetabolites 13 L1C – Vinca alkaloids and other plant products...
BioPortfolio Limited Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail TABLE OF CONTENTS ABOUT DATAMONITOR HEALTHCARE 2 About the Oncology pharmaceutical analysis team 2 CHAPTER 1 EXECUTIVE SUMMARY 6 Introduction 6 Scope and coverage of the Brief 6 Oncology portfolios key findings 9 CHAPTER 2 LEADING ONCOLOGY PLAYERS 10 CHAPTER 3 BMS: CAN THE COMPANY SUSTAIN AN ONCOLOGY...
BioPortfolio Limited Cancer Overview - Numerous Diverse Drugs Approaching Fruition TABLE OF CONTENTS About the Oncology pharmaceutical analysis team 2 Richard Faint – Director of Oncology 2 CHAPTER 1 KEY FINDINGS 3 Datamonitor insight into the oncology market 3 Key metrics 9 Datamonitor pipeline assessment summary 17 CHAPTER 2 CANCER PATIENT POTENTIAL 38 Introduction 38 Definition of cancer 38...
